Gosset Ownership
Private
Employees
~6
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Jorna Therapeutics General Information
Jorna Therapeutics is developing an AI-driven platform, SkyEngine, to design novel RNA-editing therapeutics. The company has entered a major partnership with Ono Pharmaceutical to co-develop new drugs but has not yet reported clinical results or advanced programs into human trials as of May 2025[5].
Contact Information
Primary Industry
Biotech
Corporate Office
Cambridge, MA
USA
USA
Drug Pipeline
No pipeline data available
Key Partnerships
Ono Pharmaceutical Co., Ltd. – global collaboration for discovery and development of novel RNA-editing drugs using the SkyEngine platform. Ono holds exclusive rights to discover, develop, and commercialize resulting candidates globally[5].
Jorna Therapeutics Funding
No funding data available
To view Jorna Therapeutics's complete valuation and funding history, request access »